Vol. 4 No. 2 (2023): JOURNAL OF CARDIORESPIRATORY RESEARCH

Тема статьи

APO-B/APO-A-I NISBAT KOEFFITSIENTINING YURAK ISHEMIK KASALLIGI KECHISHIDAGI O‘RNI (77-80)

Авторы

Rajabova R.Sh, Shukurdjanova S.M., Mamadiyorov A.M.

Учреждение

Toshkent tibbiyot akademiyasi

Аннотация

Tadqiqot maqsadi: Yurak ishemik kasalligi (YuIK), Zo‘riqish stenokardiyasi FS II-III bilan og‘rigan bemorlarda aterogen va antiaterogen lipoproteinlar (LP) apooqsillarining rolini, shuningdek apo-B/apo-A-I nisbatini o‘rganish. Materiallar va usullar: Tadqiqot davomida YuIK, Zo‘riqish Stenokardiyasi FS II -III tashxisi bilan 100 ta bemor tekshirildi. Bemorlarning o‘rtacha yoshi 63,3±13,4 yoshni tashkil qildi. Barcha bemorlarda qonning umumiy lipid spektri, shuningdek, apo-AI, apo-B asosiy apooqsillar miqdori tekshirildi va apo-B/apo-A-I nisbat koeffitsienti (NK) hisoblab chiqildi. Natijalar: olingan natijaga ko‘ra ZPLP XS tarkibi 3,6±0,1 mmol/l ni tashkil qilib, bu YuQT kasalliklarining rivojlanish xavfini chegara darajasiga to‘g‘ri keladi. Tadqiqotning umumiy guruhida apo-B/apo-A-I nisbati 1,31±0,01 tashkil qildi va bu YuQT kasalliklarining rivojlanish xavfi yuqori darajasiga to‘g‘ri keldi. Subklinik gipotireozning tarqalishi asosan ayollar guruhida erkaklarnikiga qaraganda 3 marta ko‘p bo‘lib, mos ravishda 28,1% va 9,3% ni tashkil etdi. Xulosa. O‘rganilgan bemorlarning ikkala guruhida ham aterogen va antiaterogen LP apo- B/apoA-I asosiy apooqsillarining konsentratsiyasining ortishi kuzatildi va bu ko‘rsatkichlar bemor holatining (AG, QD, gipotireoz, semizlik, gipodinamiya) og‘irlik darajasiga ko‘ra ortib bordi. YuIK, zo‘riqish stenokardiyasi bor bemorlarda ZPLP XS miqdori yurak-qon tomir kasalliklari xavfini oshirishida muhim ahamiyat kasb etishi aniqlandi.Tekshirilgan bemorlarda apo-B/apo-A-I NK miqdori YuQT kasalliklarining xavf chegarasiga to‘g‘ri keldi.

Ключевые слова

ateroskleroz, yurak ishemik kasalligi, aterogen va antiaterogen lipoproteinlar, apo- B/apo-A-I nisbat koeffitsienti.

Литературы

Asvold B.O., Vatten L.J., Nilsen T.I., Bjøro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study // Eur. J. Endocrinol. 2007. Vol. 156(2). P. 181–186 (33). 2. Blankstein R, Budof f MJ, Shaw LJ, Gof DC Jr, Polak JF, Lima J, Blumenthal RS, Nasir K. Predictors of coronary heart disease events among asymptomatic persons with low-density lipoprotein cholesterol MESA (Muli-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011; 58 (4):364-74. 3. El Harchaoui K, van der Steeg WA,Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Kbaw KT Boekboldt SM. Value of low density lipoprotein paeticle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5):547-53. 4. Gazi IF, T simihodimos V, T selepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense lowdensity lipoprotein particles. Expert Opin Biol Ther. 2007; 7(1):53-72. 5. Iqbal A., Jorde R., Figenschau Y. Serum lipid levels in relation to serum thyroid stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study // J. Intern. Med. 2006. Vol. 260. P. 53. 6. Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, T sunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, Katagiri T. Small LDLcholesterol is superior to LDL-cholesterol for determining severecoronary atherosclerosis. J Atheroscler Thromb. 2008;15(5):250-60. 7. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol.2011;5 (2):105-13. 8. Prieur X., Huby T., Coste H. et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5 // J. Biol. Chem. 2005. Vol. 280. P. 2753–2743. 9. Rodondi N., den Elzen W.P., Bauer D.C. Subclinical hypothyroidism and the risk of coronary heart disease and mortality // JAMA. 2010. Vol. 304(12). P. 1365–1374. 10. Srisawasdi P, Vanavanan S, Rochnawutanon M, Pornsuri yasak P, Tantrakul V, Kruthkl K, Kotani K. Heterogeneous properties of intermediate – and low density lipoprotein subpopulations. Clin Biochem 2013;46(15):1509-15. 11. Tsimihodimos V, Karabina SA, Tambaki A, Bairaktari E, Achimastos A, Tslepis A, Elisaf M. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and II B. J Cardiovasc Pharmacol. 2003;42(2):304-10. 12. Utkina EA, Afanaseva OI, Yezhov MV, Artemieva NV, Matcchin YuG, Bayda SM, Adamova IYu, Pokrovsky SN. Association between different lipoprotein subfractions and coronary aterosklerosis in middle-aged men on statin therapy. Cardiovestnik 2014; 1:68-6. Russian. 13. T.D. Chujinova, A.E. Degtyarev, T.D. Novikova Эффективность дозированном физическом нагрузки у пациентов с дислипидемиями. Seriya Meditsina. Farmatsiya. 2011 . № 10 (105).